Try our Advanced Search for more refined results
Life Sciences - April, 2020
448 articles
- DOJ Opioid Indictment Unconstitutional, Drug Distributor Says
- United Cannabis Says It Filed Ch. 11 To Stop Takeover
- Fed. Circ. Tackles Appellate Standing, Boston Scientific IP
- NY AG Slams Sacklers' Tepid Financial Info Disclosures
- Del. Justices Allow Nixing Of Biopharma Officer Salary Suit
- Canadian Pot Co. Unwinds Class Cert. Over Recalled Weed
- 10X Genomics Must Face Bio-Rad, Harvard Patent Suit
- New Pharmacy Bellwether Trial Set For 2021 In Opioid MDL
- DOL Head Says 'Cop Is On The Beat' As Virus Plan Blasted
- Dental Co. Looks To Nix High Court Arbitration Question
- 5 Great-Recession Lessons GCs Must Remember Today
- Fla. Blood Bank Donor Gets Slip-And-Fall Suit Reinstated
- Pandemic May Prompt Legislative Action On Court Deadlines
- Pandemic Creates Extra Cyber Risk For Health Care Providers
- 3D Printing Holds Promise And Risk During Pandemic
- Motions To Compel Video Deposition May Face Barriers In NY
- Del. Justices Uphold Demand For AmerisourceBergen Docs
- Becton Wins 2 Of 3 At PTAB In Medication Dosing IP Row
- Boeing Trust Smacks Teva With Another Suit Over Price Hikes
- County Says Mallinckrodt Shouldn't Get Separate Opioid Trial
- Yale Warns Workers' ADA Suit Would Set Back Wellness Plans
- J&J Beats ERISA Suit Over Asbestos In Baby Powder
- Debevoise, Kirkland Drive $250M PE Infusion For Covetrus
- Dems Say No Reopening Without 'Life-And-Death' Safety Regs
- Virus-Wary Diabetics Urge Bellwether Trials Over Insulin Costs
- CBD Co. Settles FTC Suit Over COVID-19, Cancer Cure Claims
- Coronavirus Q&A: McDermott's Health Chair
- Congress Presses FDA To Curb COVID-19 Testing Fraud
- Lax Regs, COVID-19 Impacts May Mean More Asbestos Suits
- Don't Trust Shkreli To Cure COVID-19, Feds Say
- 6 Antitrust Considerations For Companies During Pandemic
- Judging A Book: Richardson Reviews 'Criminal Dissent'
- J&J Talc Users Get One More Shot At False Ad Class Action
- Merck CEO Among Attys On NJ Virus Panel
- Teva Prevails As Judge Rules Generic Cancer Drugs Infringe
- Feds Bring More Charges In Anti-Price Gouging Campaign
- Ferring, Serenity Trial Delayed After Attys Cite Virus Concerns
- Antares Pharma Beats Suit Over 'Vague' Drug Statements
- Justices Told To Skip Challenge Over Doctrine Of Equivalents
- Enough Already With Opioid Bellwethers, Pharmacies Say
- AFL-CIO Calls DOL's Pandemic Response 'Totally Inadequate'
- Coronavirus Regulations: A State-By-State Week In Review
- NY Judge Dismisses Nabriva Investors' FDA Approval Suit
- Merck Faces Trial Over Immigrant Doctor's Revoked Job
- Accountant Says Pot Co. Fired Her For Catching Tax Scheme
- Perrigo's $163.5M Tax Trial Dates Canceled Amid Virus
- Biotech Exec's Capitalization Quarrel Panned In 2nd Circ.
- Tips For Minimizing Law Firm Liability During COVID-19
- 3 Firms Vie For Lead In Becton Securities Suit
- Cannabis Businesses Should Get Federal COVID-19 Relief
- Mass. Pot Shop's Recreational Licensing Win Tossed
- 3 Recommendations For Cos. Considering Litigation Finance
- Mass. Court Split On Making Scientist Use $10M Award On Lab
- 3 Key Developments As Coronavirus Cases Near 1,000,000
- J&J Can't Boot Experts To Sink Asbestos-In-Talc MDL
- Fed. Circ. Bars Pfizer Appeal Over Roche Antibody Drug IP
- Despite Pandemic, No One Expects OSHA Emergency Regs
- Spinal Surgeon To Pay Gov. $1.75M To Settle Kickback Claims
- Fed. Circ. Won't Revive Boston Scientific IP From Edwards IPR
- McConnell Wants Broad Liability Shield In Next COVID-19 Bill
- Judge Keeps EpiPen Expiration Date Suit Out Of MDL
- Swiss Biotech Firm, Chinese Crypto Miner Boost IPO Pipeline
- WTO Urges Members To Lift Trade Barriers On Virus Supplies
- Gilead Says Feds Used Its Research To Patent HIV Treatment
- Chancery Backs Trustee In Pharma Sale Despite 11th-Hour Bid
- Biotech Firm, Gambling Software Co. Prep IPOs Totaling $83M
- SDNY Chief Judge's May IP Trial Plan Has Lawyers Nervous
- Joint Research Considerations As Biotech Responds To Virus
- Missouri Farm Fights BASF's Bid To Escape $250M Verdict
- A Proposed Technology-Assisted Review Framework
- ERISA Doesn't Trump Drug Benefit Law, Ark. Tells High Court
- Insys Founder's Prison Report Date Pushed Back Amid Virus
- Latham Steers Cancer Therapy Biz's $200M Funding Round
- Best Ways To Use Patent Venue Discovery After TC Heartland
- US Should Decriminalize, Regulate And Tax Marijuana
- MoFo M&A Leader Leaves For Biotech Working On COVID-19
- Alphatec Cites Material Adverse Effects In Ending $122M Deal
- NY Sneaker Salesman Charged With COVID-19 Price Gouging
- Fed. Circ. Affirms Illumina's $27M Patent Win Over Ariosa
- J&J's Efforts To Toss $4.7B Talc Verdict Get Mixed Reception
- Patent Owner's Printed Publication Stance Riles PTAB Judge
- 7th Circ. Rejects Amazon Seller's $500K Trademark Appeal
- Indivior Gets Amicus Cut From 3rd Circ. Suboxone Appeal
- Express Scripts Aims To Toss Suit Over OT For 'Managers'
- Investor Sues CBD Pharma Co. Over Clinical Trial Safety Data
- Trading Firm's Arbitral Award Still Needs Some Clarity
- Fed. Circ. Won't Review Nix Of Merck's $2.5B IP Win
- Harley-Davidson, Others Targeted Over Tech Patent
- WTO Bemoans Lack Of Clarity On COVID-19 Export Curbs
- Revised N. American Trade Deal Will Take Effect July 1
- White & Case Guides Takeda In Asset Sale Worth Up To $670M
- Interlocutory Appeals In MDLs Would Burden Litigants, Courts
- The Pandemic's Impact On Pending M&A
- How Lawyers Can Find Equanimity In Crisis
- FDA Warns Trump-Touted Drugs Have Dangerous Side Effects
- Pot Investor Class Actions Doubled In Past Year
- Bausch Says Insurers Can't Skirt Coverage For Allergan Case
- Small Biz Bankruptcy Rules Come Just In Time For Many
- Ethicon Escapes Covidien Patent Claims In Device Case
- 3M Wins Restraining Order In Price-Gouging Case
- Insys Prosecutors To Appeal Part Of Landmark Guilty Verdict
- 4 Key Developments As Coronavirus Deaths Near 50,000
- Judge Says Drug IP Bench Trial A Go 'Even During Pandemic'
- EPA Pushes Crackdown On Illegal Coronavirus Disinfectants
- 11th Circ. Lets Abortions Continue In Alabama During Virus
- PTAB Won't Review DNA Patent Challenged By Illumina
- Fla. Lab, Ex-CEO Agree To Pay $37M To End SEC Fraud Suit
- SmileDirect's Calif. Dental Board Case Mostly Cut, For Now
- Drugmaker Drops Antitrust Suit Against 'Pharma Bro' Shkreli
- Coronavirus Litigation: The Week In Review
- Georgia Man Claims Zantac Caused His Stage 3 Colon Cancer
- $484B COVID-19 Relief Bill Headed To Trump's Desk
- United Cannabis Must Explain Ch. 11, Given Pot Industry Ties
- Sanofi Takes Flak Over Bid To Escape Suit During Pandemic
- 8th Circ. Clears Arkansas To Block Abortions During COVID-19
- Calif. Landlord Stuck With $6M In Fines For Illegal Pot Shops
- Cos. Making Hand Sanitizer Must Track FDA Guidance
- Calif. COVID-19 Class Actions: Early Trends And Key Defenses
- Fed. Circ. Says Drugmaker Can't Appeal Novartis PTAB Win
- Courts Should Look To 3 Bar Exam Alternatives During Crisis
- FDA Warns CBD Sellers Over Opioid Addiction Relief Claims
- How Life Sciences Cos. Can Adapt To Remote Compliance
- Patenting Personalized Nutrition Is Challenging But Feasible
- Venture-Backed Biotech Firm Raises $120M In Upsized IPO
- Gunderson Dettmer Steers Vaccine Biz's $120M Financing
- Insys Exec Tells 1st Circ. Weil Conflict Should Delay Jail Term
- HHS Vaccine Chief Says Trump Fired Him For Resisting Drug
- Hologic Can't Ban Rival's Surgical Devices After Fed. Circ. Win
- PTAB Weighs Obviousness Standard In Gene Therapy Case
- LA City Atty Says At-Home COVID-19 Test Is False Advertising
- Chancery Rejects $40M Fresenius Fee Shift In Akorn Suit
- 5 Highlights As HHS Earmarks $70B For Coronavirus Relief
- Fired Pot Worker Who Talked To DEA Can't Sue Dispensary
- EU Clears Mylan, Pfizer Unit Deal With Generics Spin Off
- Ill. City Fights Express Scripts' Probe Of Firm In Antitrust Case
- Bausch Execs Try To Nix Derivative Suit Over Fraud Scheme
- NASCAR Driver Hit With Trademark Suit From Pharma Co.
- Colo. Must Give DEA Pharmacy Data With Patient Info
- Shkreli Wants Out Of Prison To Create COVID-19 Treatment
- Liability Insurance Outlook For Opioid Public Nuisance Claims
- How AI-Related Life Sciences Patents Are Examined In Japan
- Justices Urged To End 'Extreme, Excessive' Fed. Circ. 1-Liners
- Nerve Repair Co. Axogen Beats Stock-Drop Suit
- Opioid Funds Should Be Used For Mental Health, Judge Told
- FTC Inks $38M Settlement Over Supplement False Ad Claims
- 3rd Circ. Scraps Lamictal Wholesalers' Antitrust Class Cert.
- Decision To Include Purdue In NY Opioid Trial Not Yet Ripe
- Virtual Mediation A Viable Option For Class Action Litigants
- Are Litigation Funding Documents Protected From Discovery?
- 7th Circ. Ruling Solidifies Circuit Split On Antitrust Standing
- ITC Bans Cholesterol Test Strip Imports From Chinese Co.
- McKesson Settles Derivative Suit Over DOJ Fine For $175M
- What 2 Jurisdiction Rulings Mean For Class Action Defendants
- United Cannabis Corp. Files For Ch. 11 In Colo.
- Fed. Circ. Limits Scope Of Biogen's MS Drug Patent Extension
- New York Accuses Mallinckrodt Of Opioid Insurance Fraud
- Chemours Appeals Arbitration Duty For DuPont Spinoff Bills
- How J&J's $4.7B Appeal Could Shape Missouri's Talc Trials
- Calif. Biz Groups Want Litigation Protection During Pandemic
- Roche Fights Certification Of NJ Water Contamination Class
- SEC Says Fla. Man Bilked Investors $3M In Sham Pot Co. Deal
- BASF Wants Out Of $250M Dicamba Punitive Damages Verdict
- DC Circ. Says EPA's Science Adviser Policy Unlawful
- Senate OKs $480B More Virus Relief For Small Biz, Hospitals
- UK Watchdog Looking Into Stryker's $4B Plan To Pick Up Rival
- Loestrin Buyers' Attys Seek $43M From Antitrust Deal
- More Accused Schemers Deny Horse Doping Charges
- Lawmakers Ask China To Ease Export Curbs In Virus Fight
- Life Sciences Cos. Bring Unique Real Estate Considerations
- As Zantac Litigation Accelerates, MDL Data Collection Is Key
- How COVID-19 Might Uproot Centuries Of Litigation Traditions
- Edwards Lifesciences Can Appeal Heart Device Patent Ruling
- Inovio Execs Hit With Suit On Heels Of COVID-19 Class Action
- Defending Against Nonperformance Of Life Science Contracts
- Anapol Weiss Gets Largest Share Of $3.8M Fee In Sorin MDL
- Chancellor Rips Critics Of Pharma Sale As 'Incredibly Naive'
- Drug Cos. Say Foreign Status Outs Them From Opioid Case
- UK Advances Probe Of Elanco's Sale Of Dog Ear Treatment
- 5th Circ. Bans Medication Abortion In Texas, Citing Pandemic
- Progressives Make Demands For Next Virus Relief Bill
- Insys Founder Says Feds Singling Him Out On Prison Delay
- Wilson Sonsini-Led Oric Pharmaceuticals Launches $75M IPO
- FDA Warns British CBD Seller Over Virus Prevention Claims
- Life Sciences Cos. Should Look Past Litigation During COVID
- Consider Legal Ramifications Before Recording Video Calls
- Coronavirus Q&A: Covington's Life Sciences Chair
- 3rd Circ. Is Raising Standards For Sealing Confidential Docs
- DOJ Won't Challenge Medicine Distributor During Crisis
- Opioid Cos. Hold To Drug Data Pursuit In Chicago Case
- NJ Firm Denied High Court Appeal Over $550M Mesh Award
- Epogen IP Fight Ends With Hospira Paying More Than $70M
- Akebia Gets FibroGen Anemia Drug Patents Invalidated In UK
- 'Excessive' Robins Kaplan Fee Bid Slashed In Covidien Case
- High Court Won't Hear UT's State Immunity IP Argument
- Whistleblower Can Move Gilead FCA Suit To State Court
- Fla. Panel Upholds Denial Of Medical Marijuana Licenses
- Fed. Circ. Revives Heart Monitor Patent Axed Under Alice
- Pa. Judge Rips Aventis' Last-Minute Subpoenas In FCA Fight
- KPMG's Arbitration Bid Nixed In $1.8B Drug Test Co. Fight
- AmerisouceBergen Wants Shared Docs Blocked In Del. Appeal
- Full Fed. Circ. Told Save Of Illumina DNA Patents Flouts Law
- A New Breed Of Antitrust Challenges To FDA's Orange Book
- Opioid MDL Needs New Pharmacy Bellwether, Judge Says
- 3 Tips For Deposing Difficult Witnesses Remotely
- Contract Performance During Pandemic: Lessons From 1918
- WTO Grapples With Telework Amid Coronavirus Pandemic
- Nivea Maker Beats Claims Lotion Was An Unapproved Drug
- J&J Can't Shake Texas Woman's Asbestos Talc Suit In NJ
- COVID-19 IP Catch-Up: 3M, Congress Eye Price Gouging
- UK Litigation Roundup: Here's What You Missed In London
- Treasury Vows To Expedite Iranian COVID-19 Export Requests
- High Court Delays Arguments In Birth Control, PBM Cases
- Cochlear Warns Fed. Circ. OK'd Inflated Damages Road Map
- Purdue Says Ch. 11 Stay Can't Be Lifted For NY Opioid Trial
- AbbVie Execs Want Out Of Humira Kickbacks Suit
- Labaton Sucharow Takes Lead In Cannabis Stock Drop Suit
- Manufacturers Press Mexico To Narrow Shutdown Mandate
- COVID-19 Disclosures Bring Risks For Life Sciences Cos.
- Deals Rumor Mill: General Atlantic, Naspers, Citic Securities
- How Courts Are Shaping Disclosure Of 3rd-Party MDL Funding
- Fed-Up Judge Tells Attys To 'STOP!' With Opioid Filings
- Keryx Proxy Action Ignored 'Tailored Warning,' Judge Says
- COVID-19 Test Providers, Beware Kickback Enforcement Tool
- Novartis Must Face Retaliation Suit Over Kickback Scheme
- MoFo-Led Cancer Treatment Co. Closes On $100M In Funding
- IP Policy Must Focus On COVID-19 Cure, Not Special Interests
- Drug Developer Accused Of Botching 401(k) Plan Management
- PTAB Probes Claim Construction Standard In Dental IP Case
- Fed. Circ. Ruling Lets PTAB Keep Close Eye On Amendments
- J&J Must Face Retrial In Pa. Pelvic Mesh Injury Case
- House Dems Target Exclusivity, Pricing Of COVID-19 Drugs
- Fla. Pain Clinic, Lab To Pay $41M To Settle FCA Claims
- Rice University Pays $3.7M To End Grant Misuse Claims
- Latham Steers Pharma Co. In $100M Follow-On Offering
- Feds Say Medicare Dispute Invalidates True Health Ch. 11 Plan
- Missouri Settles First Complaints About Medical Pot Licensing
- Ex-Theranos CEO's Criminal Trial Delayed Until October
- PTAB Axes University Of Chicago Cancer Treatment Patent
- CARES Act Will Accelerate OTC Drug Development
- Last Doctor Charged In $5M Opioid Ring Will Plead Guilty
- Fed. Circ. Won't Revisit Battle Over Sensipar Generics
- COVID-19 Securities Class Actions May Hinge On Disclosures
- Emerging Trends In COVID-Related Commercial Litigation
- New Jersey's Plan For 2020 Law Grads Is Brilliant
- NY Businessman Settles SEC's Microcap Fraud Suit For $3.5M
- Drug Cos. May Find Real-World Evidence Cuts Both Ways
- Health Hires: Jones Day, Wilson Sonsini, King & Spalding
- 6th Circ. Limits Opioid Claims Against Pharmacies
- Trump Vows Openings By May, Blames WHO For Pandemic
- 5 New COVID-19 Abortion Developments You Should Know
- Ex-Theranos CEO Seeks 2021 Trial After New Charges Emerge
- Coronavirus Regulations: A State-By-State Week In Review
- Calif., 5 Other States Join Antitrust Suit Against Shkreli
- Zimmer Biomet Agrees to $50M Investor Settlement
- Managing E-Discovery Providers In Times Of Crisis
- To Tackle COVID Price Gouging, 3M Turns To Trademark Law
- Brain Disease Research Co. Raises $45M In Funding Round
- COVID-19 Hacks Bring Cyber Hygiene Into Sharp Focus
- Witness Preparation Tips For Your Next Video Deposition
- How 3rd Parties Can Best Limit Fraud Liability Amid COVID-19
- Cooley-Repped Life Sciences Group Prices $121M Offering
- Sanofi, GSK Team Up To Create COVID-19 Vaccine
- 3 Developments As Trump Claims 'Total' Virus-Rebound Power
- BASF Can't Skirt $250M In Dicamba Damages, Monsanto Says
- The Impact Of Distinct Printed Publication Rules In Exams, IPR
- Teva Unit To Pay $540K EPA Fine Over Clean Air, Water Claims
- Mass. Cannabis Regulator Says She's Stepping Down
- Cherokee Tribe Fires Opening Salvo In Opioid Bellwether
- Hemp Co. Says Calif. County Illegally Destroyed $1B Crop
- Takeaways From FDA's Relaxed Rules For Making Face Masks
- Use Of AI To Treat COVID-19 Shows Novel Inventorship Issues
- Coronavirus Q&A: Sidley Austin's Health Practice Chairs
- Upping Hospitals' Liability Defenses For COVID Measures
- Justices Urged To Wade Into Texas' COVID Abortion Ban Fight
- Law360's 2020 Life Sciences Editorial Advisory Board
- Insys Execs Should Stay In Jail During Appeal, Gov't Says
- In Defense Of Virtual Mediation
- 3 Firms Forge Blackstone's $2B Alnylam Pharma Investment
- Fed. Circ. Weighs Undoing $24M Verdict In DNA IP Row
- Fed. Circ. Orders New Trial In Alere Urine-Test Patent Case
- House Dems Seek FTC Answers On Ventilator Maker Merger
- Pharma Cos. Slam Opioid Negotiation Class At 6th Circ.
- Arthrex Asks Justices To Tackle 2 IPR Constitutional Issues
- Telehealth's Not Getting Switched Off After COVID-19 Crisis
- Ballot Backers Ask Calif. Appeals Court To Uphold SF Tax Vote
- 2nd Circ. Won't Rehear Deerfield Insider Trading Appeal
- MDLs Need A New Path To Interlocutory Appeals
- Jailed Pharma Exec Claiming COVID-19 Risk Denied Release
- Pharma Research Co. Accused Of Firing Whistleblowing Exec
- Del. Justices End Suit Over Walgreens' Theranos Deal
- A Call To Action For The Coming Insurance Litigation Siege
- J&J Drops $400M Deal For Takeda's Surgical Patch
- Some Public Nuisance Claims Cut In NY Opioid Suit
- Strategies For Discouraging Nuisance Patent Suits
- 3M Files Trademark Suit Over COVID-19 Mask Price-Gouging
- How A Small Law Firm Adapts To Remote Work
- Don't Just Delay The Bar Exam — Cancel It Forever
- Life Science Cos. Navigate Dicey Path To Public Markets
- Gilead Rips Merck's New Bid To Restore $2.5B Patent Verdict
- Ex-CEO's Threat To Kill Prosecutor Snarls COVID Release Bid
- 4 Key Developments As Coronavirus Nears Possible Peak
- Fla. Health Workers Say China Is Hoarding Protective Supplies
- Daiichi Says Court Should Decide Drug Patent Fight Venue
- Fed. Circ. Revives Nevro Spine Pain IP Axed As Indefinite
- Calif. Small Businesses Sue China For $8T Over COVID-19
- FDA Warns InfoWars Over COVID-19 Claims
- Fed. Circ. Backs EDTX Decision Clearing Needle Co. In IP Suit
- High Court Inaction Paves Way For Increasing FCA Dismissals
- Early Securities Class Actions Highlight COVID Litigation Risk
- Ex-Zimmer Exec's Discharge Claim Cut From Sex Bias Case
- Amazon To Fight Ex-Worker's Medical Pot Suit In State Court
- 1st Circ. Finds No Fraud In Ocular Therapeutix Stock Suit
- Coronavirus Litigation: The Week In Review
- 7th Circ. Is Told National Class Can't Stay In Ill. TCPA Suit
- How Sellers Can Avoid Price-Gouging For 'Essential' Cannabis
- Don't Forget Firm Culture When Adapting To Remote Work
- COVID-19 Test Maker Hits 'Nefarious' Co. With TM Suit
- Juno Awarded Over $1.1B In Final Judgment For IP Case
- Pfizer Beats Viagra MDL After Plaintiffs' Experts Booted
- Intel, Universities Support Freeing Up IP To Fight COVID-19
- Fed Circ. Revives Mylan Bid To Invalidate Relistor Patent
- Fed. Circ. Rules BASF's Polymer Patent Row Wrongly Axed
- GM, Philips Getting $1.1B For Coronavirus Ventilators
- EU Open To 'Comforting' Drugmakers Cooperating Amid Virus
- COVID-19 Countermeasure Protections Are Not Absolute
- 1st Circ. Backs NuVasive's Noncompete With Ex-Sales Rep
- NY AG Seeks Additional Sackler Family Financial Info
- Does COVID-19 Fall Under Insurers' Pollution Exclusions?
- Okla. Wants To Enforce PBM Law Amid COVID-19 Crisis
- FDA Warns More CBD Sellers About Bogus COVID-19 Claims
- SEC Suspends 3 More OTC Stocks Over COVID-19 Concerns
- Cooley-Led BioPharma Raises $96M In IPO At Top Of Range
- J&J Unit Beats Suit Over Defective Breast Implants
- Predicting COVID-19's IP Impact From Past Recessions' Stats
- Antitrust Regulator Suspends Drug Price Probes Amid Virus
- Trump Fleshes Out Export Restrictions On Medical Equipment
- Suit Faults Carnival Unit For 'Ticking Coronavirus Time Bomb'
- Can Cannabis Survive the Virus? Hemp Has A Leg Up
- Calif. Justices Open To Cities Seeking Statewide UCL Relief
- Cahill Gordon Suspends 2020 Summer Associate Program
- Pentax Reaches $43M DOJ Deal Resolving Scopes Charges
- Pfizer Dodges Suit Claiming Lipitor Causes Diabetes
- Sun Pharma Must Face Celgene's Suit Over Generic Revlimid
- Drug Buyers Cut New, Smaller Antitrust Deal With Celgene
- Puerto Rico Board Says COVID-19 Test Kit Orders Broke Law
- Prosthetics Cos. To Divest Business To Allay FTC Concerns
- Mallinckrodt CEO Must Face Deposition In City's Acthar Fight
- 10th Circ. Upholds IRS Summonses For Marijuana Co.'s Info
- Telehealth Startup Involved In Virus Efforts Raises $50M
- Grassley, Neal Seek Tariff Info On Coronavirus Supply Imports
- 5th Circ. Ruling Amplifies Bristol-Myers Class Action Debate
- Greenberg Traurig Fights Conflict Claim In $1B Fraud Suit
- Conducting Court Hearings Remotely: 12 Considerations
- 7 Ways COVID-19 Product Makers Can Mitigate IP Infringement
- Pandemic May Spur Reform Of Lab Test Regulation
- Mylan Investors Get Cert. In EpiPen Securities Fraud Action
- 3 Key Developments As Coronavirus Deaths Top 10,000
- Trump Unveils Deal With 3M To End Mask Production 'Saga'
- Clinic Says ED Treatment Co. Blocking Competition
- Chancery Sets Short Sale Fuse For Troubled Drug Company
- How COVID-19 Could Shake Up Patent Strategies
- Claims Cut From Opioid MDL's Hospital Bellwether
- Aurobindo, Heritage Accused Of Hiding Drug Contamination
- Firm Cost-Cutting Has GCs Watchful But Not Worried — Yet
- SEC Halts Trading For 2 Penny Stocks Over COVID-19 Claims
- 3rd. Circ. Says Press Release Didn't Defame Pharma Co.
- Bayer Looks To Scratch Antitrust Suit Over Flea, Tick Med
- Ex-FTC Atty Leaves Boies Schiller For Davis Wright
- LA City Atty Settles Suit Over Fake At-Home COVID-19 Tests
- Catalent Must Face Fired Worker's Suit Over False Records
- Pa. Panel Says Ballard Spahr Can Arbitrate Malpractice Case
- Arizona Dispensary Warned For Claiming Products Treat Virus
- DOJ OKs Medical Supply Partnership For COVID-19 Response
- 7th Circ. Told New State Law Doesn't Fix Smokable Hemp Ban
- Mylan Gets PTAB To Nix Sanofi's Lantus Patent Claim
- Key CARES Act Implications For Health And Life Sciences
- Schumer Calls For Military 'Czar' To Oversee Medical Supplies
- Baxter, Hospira Beat Saline Price-Fixing Class Action Again
- E-Cigarette Deadline Extended Amid COVID-19 Pandemic
- International Orgs Rally To Preserve COVID-19 Supply Chain
- The Era Of Video Mediation Is Here — Or Is It?
- High Court Won't Hear Respiratory Treatment Patent Suit
- COVID-19 Highlights BigLaw Need For Emotional Intelligence
- D&O Insurance Tips For Coronavirus-Related Claims
- High Court Won't Weigh DOJ Dismissal Power In FCA Cases
- Ex-Hospital Owner Sanctioned For Holding Info In Clinic Fight
- States' Suit Touted For Bellwether In Generics Price-Fix Case
- Chancery Finds Fraud In Cancer Drug Firm's Spinoff Deal
- Fed. Circ. Lifts Bar On Eye Device Maker's Speech In IP Fight
- Justices Asked To Clarify Gateway Arbitration Question
- Pot Co. Acreage Scraps $120M Deal Amid Virus Cutbacks
- Venture-Backed Firms Could Miss Out On Virus Relief Loans
- Ex-Employees Say $5.5M Deal Can't Stop Retaliation Suit
- Key Issues As Automakers Shift To Medical Device Production
- Will COVID-19 Transform The Cannabis Industry?
- WTO Charts Lofty Tariffs On Essential COVID-19 Supplies
- Melinta's Ch. 11 Exculpation Runs To Plan Date, Court Rules
- The Pandemic's Early Effects On Foreign Trade, Investment
- Judicial Shaming Of Attys Is Troubling Even During Pandemic
- McKesson Again Wants Out Of Antitrust-Linked Derivative Suit
- 3M Hits Back After Trump's Call To Stop Exporting N95 Masks
- What It's Like To Join A Law Firm In The COVID-19 Era
- Don't Be Social Media Distancing: LinkedIn Tips For Lawyers
- Health Hires: Akin Gump, K&L Gates, EIP, Oric Pharma
- Supreme Court Postpones April Argument Session
- Novartis And Aurobindo Scrap $900M Deal Amid FTC Probe
- 19 Deny Charges In Alleged Horse Doping Scheme
- Federal Law Stops Pot Investor From Recovering $4.7M Loans
- IRS Wrongly Kept $400K From Electronic Parts Co., Suit Says
- Minn. AG's Insulin Pricing Suit Survives, Minus RICO Claims
- CBD Co. Latest Target In COVID-19 Scam Enforcement
- Eli Lilly Says Genentech Owes $10M In 'Unwinnable' Suit Fees
- Melinta Gets OK For Ch. 11 Equity Swap Plan With Creditor
- Defending Against A Wave Of Hand Sanitizer Class Actions
- Animal CBD Dealer Sued For Shorting Supplier On $6M Deal
- Emergency Laws Protect Cos. Enlisted In COVID-19 Fight
- 'Pharma Bro' Shkreli Aims Another Blow At Kidney Drug Suit
- Remote Depositions: Coming To A Home Office Near You
- Ways Lawyers Can Support The Most Vulnerable Right Now
- Virus Heightens Importance Of Drug Shortage Reports To FDA
- COVID-19 Shows Need For Stronger Diagnostic IP Protection
- Merck, Takeda Unit Beat Off-Label FCA Kickbacks Suit
- VC Firm Closes On $1.1B Fund For New Biotech Cos.
- Arch Snags $1.46B For Pair Of Biotech-Focused Funds
- IRS May Have Missed $243M In Pot Biz Taxes, TIGTA Says
- Insurance Groups Tell Justices PBM Law Would Upend ERISA
- 10x Genomics Reveals Ransomware Attack Amid Pandemic
- Justice Delayed: Coronavirus Halts Opioid, Cancer Trials
- UK Man Snuck Fake Coronavirus Meds Into Calif., Feds Say
- Hemp Co. Says Seed Producer Cutting It Out of US Sales
- Promoter Disclosed 'Cobra Venom' Co. Payment, Judge Says
- Fed Agencies Flag Ex-NFLer For Claiming CBD Cures Virus
- Pfizer Gets Rival's Epinephrine Injection Patent Killed
- Fed. Circ. To Air Live Audio Of Oral Arguments Amid COVID-19
- Canadian Cannabis Grower To Restructure With $2.8M Loan
- Senate Bill Would Expand Term For COVID-19 Treatment IP
- Theranos Judge Rips 'Tone' Of Attys' Pandemic-Related Filing
- Pharmacies' Doctor Claims Dropped From Ohio Opioid MDL
- Ex-Rep. Collins Asks To Delay Sentence Over COVID-19
- Autoimmune Therapy Biz Raises $80M In Series B Round
- PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly
- What If Gov't Allows Patent Infringement For COVID-19 Drugs?
- Telehealth During COVID-19: New Rules And Considerations
- FDA Orders Heartburn Meds Off Shelves Over Cancer Risk
- Cooley-Led Life Sciences Firm Seeks To Raise $75M In IPO
- EU To Suspend VAT On Medical Supplies Amid Pandemic
- Confronting The Challenges Of Virtual Mediation
- Akorn Says Credit Default Brings It To Brink Of Bankruptcy